← Leaderboards
Neal Flomenberg
Thomas Jefferson University
$3,074,753
Attributed
$3,074,753
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $992.9K · FY2009–10$1M$750K$500K$250K$0
'09
'10
Funding mix
By agency
NIH$5,344,731 · 4
By mechanism
P01$2,688,619 · 2
RC2$1,953,226 · 1
R21$702,886 · 1
Top collaborators
No co-investigators on record.
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Robert Korngold$9,942,144
- Gudrun Philomena Debes$6,518,089
- Carlo M Croce$37,904,390
- David S Strayer$8,559,654
- Thea Friedman$3,221,424
Others in their field
Top investigators on “Graft Versus Host Disease”
- Mary M Horowitz · Medical College Of Wisconsin$91,475,733
- Bruce R. Blazar · University Of Minnesota$42,260,909
- Effie W Petersdorf · Fred Hutchinson Cancer Research Center$35,600,148
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$31,342,499
- Pavan Reddy · University Of Michigan At Ann Arbor$27,447,362
- Leslie S Kean · Emory University$25,182,346
Research focus
Graft Versus Host DiseaseHomologous TransplantationImmunosuppressiveBone Marrow TransplantationHuman Therapy EvaluationHistocompatibilityCd4 MoleculeHuman SubjectCyclic PeptidesAllogenicCell CountDiarrheaCell TypeCharacteristicsAggressive Clinical CourseAdverse EffectsCaringCommunitiesClinical Trial Phase IAfrican AmericanCounselingClinical ResearchClinical ApplicationBlood
Grant awards (8)
Matched and Haploidentical transplantation for Adults with Sickle Cell Anemia$960,323
RC2 · FY2010 · HL · contact PI
Matched and Haploidentical transplantation for Adults with Sickle Cell Anemia$992,903
RC2 · FY2009 · HL · contact PI
LLME TREATED T LYMPHOCYTE THERAPY AFTER ALLOGENEIC BMT$353,250
R21 · FY2002 · CA
BIOLOGIC &CLINICAL PROPERTIES OF CD4 STRUCTURAL ANALOGS$1,143,006
P01 · FY2001 · CA
LLME TREATED T LYMPHOCYTE THERAPY AFTER ALLOGENEIC BMT$349,636
R21 · FY2001 · CA
EFFICACY AND TOXICITY OF CD4 PEPTIDE 802-2 IN HUMAN UNRELATED DONOR BONE MARROW$196,218
P01 · FY2001 · CA
BIOLOGIC &CLINICAL PROPERTIES OF CD4 STRUCTURAL ANALOGS$1,126,972
P01 · FY2000 · CA
EFFICACY AND TOXICITY OF CD4 PEPTIDE 802-2 IN HUMAN UNRELATED DONOR BONE MARROW$222,423
P01 · FY2000 · CA